B细胞-话题@MedSci

#B细胞#

314篇内容 | 4755人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273380, encodeId=25ce12e338053, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合, objectType=article, longId=204989, objectId=3fcf20498994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fcf20498994, replyNumber=0, likeNumber=70, createdTime=2020-12-31, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fcf20498994, moduleTitle=Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fcf20498994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273379, encodeId=667212e337983, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, objectType=article, longId=204967, objectId=9ede20496e6a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ede20496e6a, replyNumber=0, likeNumber=72, createdTime=2020-12-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ede20496e6a, moduleTitle=Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ede20496e6a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273378, encodeId=b85e12e3378e9, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Commun :艾滋病疫苗新理念，回输编程B细胞产生广谱中和抗体, objectType=article, longId=203767, objectId=c468203e679d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c468203e679d, replyNumber=0, likeNumber=87, createdTime=2020-11-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c468203e679d, moduleTitle=Nat Commun :艾滋病疫苗新理念，回输编程B细胞产生广谱中和抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c468203e679d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273377, encodeId=962312e337723, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：血红色可抑制SCD患者的体液B细胞反应调控同种免疫风险, objectType=article, longId=203745, objectId=3cc7203e4534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc7203e4534, replyNumber=0, likeNumber=53, createdTime=2020-11-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc7203e4534, moduleTitle=Blood：血红色可抑制SCD患者的体液B细胞反应调控同种免疫风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc7203e4534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273376, encodeId=7dc712e3376a5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：家族性B细胞前体-急性淋巴细胞白血病的胚系PAX5突变, objectType=article, longId=201968, objectId=46da2019686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46da2019686d, replyNumber=0, likeNumber=72, createdTime=2020-10-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46da2019686d, moduleTitle=Blood：家族性B细胞前体-急性淋巴细胞白血病的胚系PAX5突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46da2019686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273375, encodeId=8b2212e33756c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施, objectType=article, longId=201786, objectId=f16c201e869b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f16c201e869b, replyNumber=0, likeNumber=30, createdTime=2020-10-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f16c201e869b, moduleTitle=Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f16c201e869b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273374, encodeId=e67e12e337461, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, objectType=article, longId=201329, objectId=4e25201329bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e25201329bf, replyNumber=0, likeNumber=138, createdTime=2020-09-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e25201329bf, moduleTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e25201329bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273373, encodeId=ed0312e33735c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征, objectType=article, longId=200528, objectId=731c200528e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=731c200528e0, replyNumber=0, likeNumber=54, createdTime=2020-09-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=731c200528e0, moduleTitle=Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=731c200528e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273372, encodeId=ad7412e337203, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高, objectType=article, longId=200150, objectId=af16200150b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af16200150b6, replyNumber=0, likeNumber=69, createdTime=2020-09-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af16200150b6, moduleTitle=Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af16200150b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273371, encodeId=687a12e337178, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, objectType=article, longId=199785, objectId=1282199e85f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1282199e85f7, replyNumber=0, likeNumber=93, createdTime=2020-08-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1282199e85f7, moduleTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1282199e85f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273370, encodeId=150312e33700d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, objectType=article, longId=199756, objectId=08d0199e56b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08d0199e56b3, replyNumber=0, likeNumber=86, createdTime=2020-08-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08d0199e56b3, moduleTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08d0199e56b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273369, encodeId=145712e336996, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, objectType=article, longId=199630, objectId=6d341996303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d341996303b, replyNumber=0, likeNumber=123, createdTime=2020-08-19, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d341996303b, moduleTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d341996303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273368, encodeId=03e012e336847, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：新亚型——组织常驻型记忆B细胞, objectType=article, longId=199401, objectId=c61a199401dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c61a199401dc, replyNumber=0, likeNumber=62, createdTime=2020-08-15, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c61a199401dc, moduleTitle=Blood：新亚型——组织常驻型记忆B细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c61a199401dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273367, encodeId=d69f12e33672b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nature：肠道微生物影响B细胞和抗体库, objectType=article, longId=199141, objectId=9c0d19914123, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0d19914123, replyNumber=0, likeNumber=60, createdTime=2020-08-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0d19914123, moduleTitle=Nature：肠道微生物影响B细胞和抗体库, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0d19914123)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273366, encodeId=f71912e33666f, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, objectType=article, longId=199079, objectId=eb231990e923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb231990e923, replyNumber=0, likeNumber=73, createdTime=2020-08-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb231990e923, moduleTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb231990e923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273365, encodeId=7a3d12e336511, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=76, createdTime=2020-08-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273364, encodeId=432812e3364ca, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？, objectType=article, longId=198182, objectId=94ab1981822a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ab1981822a, replyNumber=0, likeNumber=64, createdTime=2020-07-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ab1981822a, moduleTitle=Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ab1981822a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273363, encodeId=2f9e12e336385, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后, objectType=article, longId=197418, objectId=96e319e4187d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e319e4187d, replyNumber=0, likeNumber=83, createdTime=2020-07-14, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e319e4187d, moduleTitle=Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96e319e4187d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273362, encodeId=50a612e3362b0, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, objectType=article, longId=197011, objectId=7c6419e01122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6419e01122, replyNumber=0, likeNumber=76, createdTime=2020-07-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6419e01122, moduleTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6419e01122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273361, encodeId=7b3112e336198, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值, objectType=article, longId=196957, objectId=85b019695ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b019695ede, replyNumber=0, likeNumber=93, createdTime=2020-07-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b019695ede, moduleTitle=Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b019695ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Br J Cancer：SBI-756 + venetoclax：新型B细胞淋巴瘤治疗组合

2020-12-31

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Br J Cancer：药物RO6870810对NUT中线癌、其他实体瘤或弥漫性大B细胞淋巴瘤患者的治疗效果

2020-12-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Commun :艾滋病疫苗新理念，回输编程B细胞产生广谱中和抗体

2020-11-27

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：血红色可抑制SCD患者的体液B细胞反应调控同种免疫风险

2020-11-27

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：家族性B细胞前体-急性淋巴细胞白血病的胚系PAX5突变

2020-10-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Biol Blood Marrow Transplant：异基因干细胞移植为原发性纵隔大B细胞淋巴瘤患者提供了持久的缓解措施

2020-10-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素

2020-09-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征

2020-09-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高

2020-09-04

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次

2020-08-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤

2020-08-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020-08-19

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：新亚型——组织常驻型记忆B细胞

2020-08-15

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nature：肠道微生物影响B细胞和抗体库

2020-08-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响

2020-08-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2020-08-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？

2020-07-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后

2020-07-14

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤

2020-07-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值

2020-07-04

科室
- - 订阅+
  - 更多科室
工具
服务